denkapparat Operations
TVTX icon

denkapparat Operations’s Travere Therapeutics TVTX Stock Holding History

denkapparat Operations’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$391K Hold
6,634
– – 0.1% 338
2026
Q2 		$377K Buy
+6,634
New +$294K 0.12% 301
2026
Q1 		– Sell
-6,634
Closed -$253K – 361
2025
Q4 		$253K Buy
+6,634
New +$216K 0.14% 262

Other funds holding TVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

denkapparat Operations's TVTX Position: Q3 2026 in Review

denkapparat Operations held its Travere Therapeutics (TVTX) position steady in Q3 2026 at 6,634 shares worth $391K. The position accounts for 0.1% of the portfolio, ranked #338.

denkapparat Operations first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 198 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • denkapparat Operations held 6,634 shares of Travere Therapeutics worth $391K as of Q3 2026.
  • denkapparat Operations left its Travere Therapeutics share count unchanged in Q3 2026.
  • Travere Therapeutics made up 0.1% of denkapparat Operations's portfolio in Q3 2026, its #338 holding.
  • denkapparat Operations first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 198 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on denkapparat Operations's 13F filing for Q3 2026, filed 9 Nov 2026.